B

ig-name investors have poured money into developing “liquid biopsies” — blood tests intended to diagnose early-stage cancer in asymptomatic patients.

But is a pan-cancer blood test clinically realistic? The jury’s still out, in part because each individual’s cancer is different, and certain tumors can be stunningly complex.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.